Chat with us, powered by LiveChat

Castration-resistant Prostate Cancer Treatment Market (Therapy Type - Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy; Drug Delivery Method - Oral Route, and Injectable Route; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Castration-resistant Prostate Cancer Treatment Market (Therapy Type - Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy; Drug Delivery Method - Oral Route, and Injectable Route; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR0414 Category: Healthcare & Medical Devices Published: November, 2023

A recent report published by Infinium Global Research on castration-resistant prostate cancer treatment market provides in-depth analysis of segments and sub-segments in the global as well as regional castration-resistant prostate cancer treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional castration-resistant prostate cancer treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global castration-resistant prostate cancer treatment market.

Market Insight:

The global castration-resistant prostate cancer treatment market was valued at USD 10.11 billion in 2022 and is expected to reach USD 19.35 billion in 2030, with a CAGR of 8.51% during the forecast period 2023-2030.

In the healthcare industry, the Castration-resistant Prostate Cancer (CRPC) treatment market plays a pivotal role. It contributes to a critical unmet need to treat advanced prostate cancer. The castration-resistant prostate cancer market involves the development, production, and dissemination of dedicated therapies and pharmaceuticals dedicated to combating CRPC. This CRPC has been recognized as resistant to conventional hormone treatments. The market is characterized by strong involvement from different entities, including biotechnology firms, pharmaceutical companies, and healthcare providers. These entities are responsible for the research and development, along with the distribution of innovative treatment solutions. The growth and development of such areas as research and development are significant the escalating demand for tailored and effective therapies. These therapies support to recovery from advanced prostate cancer, further presenting growth opportunity for the market during the projected period.

The rising investment in the development of novel therapies such as targeted therapies and immunotherapies, propels the growth of the castration-resistant prostate cancer treatment market over the projected period. The development of novel therapies offering advanced options for patients to recover from cancer and support pharmaceutical companies to expand their product portfolio to hold a prominent place in the market. In addition to this, the increasing number of patients suffering from castration-resistant prostate cancer is contributing to the expansion of the market. The rising number of patients is closely linked to the continuously growing aging population. Castration-resistant prostate cancer is mostly seen among the old age population. The increasing number of old age population creates the need for effective treatments. This further creates a substantial market opportunity for pharmaceutical companies operating in the Castration-resistant Prostate Cancer (CRPC) treatment medication. However, the continuously rising treatment costs present a significant barrier to the widespread adoption of the treatment and further limits the growth of the market. Although, the continuous advancements in precision medicine and the identification of novel biomarkers offer a promising growth opportunity for the Castration-resistant Prostate Cancer (CRPC) treatment market over the projected period.

Castration-resistant Prostate Cancer Treatment Market | IGR

North America is expected to grab a significant market share in the Castration-resistant Prostate Cancer (CRPC) treatment market during the projected period. Owing to the prevalence of diseases in the region. Apart from this, North America involves the presence of key market players. These market players invest significantly in research and development. In addition, the favorable reimbursement policies in North America are also contributing to the growth of the castration-resistant prostate cancer treatment market over the period. Additionally, ongoing investment in the advancement of healthcare technology and a growing focus on the development of innovative and effective treatments for castration-resistant prostate cancer contributes to the growth of the market in the North American region in the upcoming forecast period. Furthermore, the Asia Pacific region is expected to hold the highest growth rate in the global market during the forecast period. The primary reason for the growth Castration-resistant Prostate Cancer (CRPC) treatment market in the Asia-Pacific region is the growing development of healthcare infrastructure in the region, mainly in the nations such as China and Japan.

Report Scope of the Castration-resistant Prostate Cancer Treatment Market:

Report Coverage Details
Market Size in 2022 USD 10.11 Billion
Market Size by 2030 USD 19.35 Billion
Growth Rate from 2023 to 2030 CAGR of 8.51%
Largest Market North America
No. of Pages 255
Market Drivers
  • The development and introduction of novel treatments, such as targeted therapies and immunotherapies, drive growth in the castration-resistant prostate cancer treatment market.

  • The increasing prevalence of castration-resistant prostate cancer fuels the market growth.

Market Segmentation By Therapy Type, By Drug Delivery Method, and By Distribution Channel
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global castration-resistant prostate cancer treatment market covers segments such as therapy type, drug delivery method, and distribution channel. On the basis of therapy type, the sub-markets include chemotherapy, hormonal therapy, immunotherapy, and radiotherapy. On the basis of drug delivery method, the sub-markets include oral route, and injectable route. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, and online pharmacies.

The report provides profiles of the companies in the market such as Pfizer Inc., Astellas Pharma Inc., Johnson & Johnson, Inc., Sanofi, Novartis AG, Bayer AG, GSK plc., Northwest Biotherapeutics, Inc, Active Biotech AB, and Dendreon Pharmaceuticals LLC.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the castration-resistant prostate cancer treatment market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global castration-resistant prostate cancer treatment market was valued at USD 10.11 Billion in 2022.
It is likely to grow at a CAGR of 8.51% during the forecast period 2023-2030.
The global castration-resistant prostate cancer treatment market is estimated to reach USD 19.35 Billion by the end of 2030.
North America is anticipated to exhibit high demand for castration-resistant prostate cancer treatment market during the forecast period.
Pfizer Inc., Astellas Pharma Inc., Johnson & Johnson, Inc., Sanofi, Novartis AG, Bayer AG, GSK plc., Northwest Biotherapeutics, Inc, Active Biotech AB, and Dendreon Pharmaceuticals LLC..
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.